Furthermore, regarding anti-inflammatory activity, CIGB-258 showed similar features to an IL-6 inhibitor (Tocilizumab) than a TNF-α inhibitor (Infliximab) to protect zebrafish and embryos from acute death by CML treatment. Here, IL6 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.